Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Calcific Aortic Valve Stenosis (VERIFICATION)
NCT07715279Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Vericiguat oral suspension (Formulation 4) in calcific aortic valve stenosis (CAVS) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Change in Aortic Valve Calcium Score at 24 months. Started Sep 2026; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
calcific aortic valve stenosis (CAVS)
Beyond the preview
Go deeper on NCT07715279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715279.